ClouDr Group Limited (9955) AI Stock Analysis

• Market Cap: HK$887.94M
• Dividend Yield: N/A
• Average Volume (3M): 3.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: -43.86%
• EPS Growth: -217.25%
• Country: HK
• Employees: 1,218
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Distribution
• EPS (TTM): -1.00
• Shares Outstanding: 645,718,800
• 10 Day Avg. Volume: 2,983,893
• 30 Day Avg. Volume: 3,126,157
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.50
• Price Target Upside: 8.70% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: HK$1.50 ▲(8.70% Upside)

ClouDr Group Limited faces significant challenges with profitability and cash flow, reflected in a low financial performance score. Technical indicators suggest a bearish trend, and the negative P/E ratio highlights valuation concerns. These factors collectively result in a low overall stock score.

ClouDr Group Limited Business Overview & Revenue Model

Company Description

ClouDr Group Limited (9955) is a Chinese company that specializes in providing digital solutions for the healthcare industry. The company focuses on offering cloud-based services and platforms to healthcare providers, enhancing the efficiency and quality of healthcare delivery. Its core products and services include electronic health records, telemedicine solutions, and healthcare data analytics, which are designed to streamline operations and improve patient outcomes.

How the Company Makes Money

ClouDr Group Limited generates revenue primarily through subscription fees for its cloud-based healthcare platforms and services. The company offers its digital solutions on a subscription basis to hospitals, clinics, and other healthcare providers, enabling them to access and utilize its technology to improve operational efficiency and patient care. Additionally, ClouDr may engage in partnerships with other companies or healthcare institutions to expand its market reach and enhance its service offerings. Revenue can also be supplemented by providing value-added services such as data analytics and customized healthcare IT solutions tailored to the specific needs of its clients.

ClouDr Group Limited Financial Statement Overview

Summary

ClouDr Group Limited is experiencing growth in revenue, but profitability remains a challenge with persistent net losses. Improvements in balance sheet metrics such as leverage and equity ratio are positive signs, yet historical negative equity and high liabilities are concerning. The company’s cash flow situation is precarious, relying heavily on external financing, which could impact future liquidity.

Income Statement

ClouDr Group Limited shows a consistent increase in revenue over the years, with a significant jump from 2020 to 2021. However, the company is still operating at a loss, with net losses increasing over time. The gross profit margin has remained stable, indicating efficient cost management. The negative EBIT and EBITDA margins highlight ongoing operational challenges, and the declining net income margin raises concerns about profitability in the near term.

Balance Sheet

The company's debt-to-equity ratio has improved over time, suggesting better leverage management. However, the negative stockholders' equity in earlier years indicates historical financial difficulties. The equity ratio has improved, reflecting better asset management. Despite positive trends, the company's past negative equity and high liabilities pose risks.

Cash Flow

Despite generating negative free cash flow consistently, ClouDr Group Limited managed to improve operating cash flow over recent years. The operating cash flow to net income ratio indicates that the company is still struggling with cash generation relative to its income losses. The reliance on financing activities for cash sustenance could pose liquidity risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.49B	3.69B	2.99B	1.76B	839.12M
Gross Profit	861.67M	909.38M	792.10M	570.02M	232.76M
EBITDA	-372.34M	-208.37M	-1.58B	-4.06B	-2.86B
Net Income	-516.41M	-323.06M	-1.69B	-4.14B	-2.87B
Balance Sheet
Total Assets	2.84B	2.95B	2.83B	2.51B	1.69B
Cash, Cash Equivalents and Short-Term Investments	525.84M	752.96M	723.17M	1.12B	914.23M
Total Debt	581.24M	267.05M	228.67M	124.31M	358.62M
Total Liabilities	1.41B	1.18B	953.05M	9.66B	5.08B
Stockholders Equity	1.45B	1.83B	1.85B	-7.14B	-3.36B
Cash Flow
Free Cash Flow	-225.19M	-263.46M	-809.87M	-755.02M	-478.99M
Operating Cash Flow	-148.39M	-140.43M	-642.63M	-666.33M	-438.46M
Investing Cash Flow	66.87M	-38.34M	-744.94M	-155.50M	-160.20M
Financing Cash Flow	147.99M	171.81M	503.55M	1.02B	918.41M

ClouDr Group Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Neutral. The current price of 1.38 is below the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.42, and above the 200-day MA of 1.28, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 5.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9955.

ClouDr Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1931	65 Neutral	HK$17.69B	94.05	5.07%	0.83%	0.33%	-44.28%
2192	65 Neutral	HK$9.91B	28.26	6.77%	1.98%	29.81%	10.40%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
9955	39 Underperform	HK$887.94M	―	-69.05%	―	-43.86%	-217.25%
2289	―	HK$637.20M	12.22	8.12%	8.23%	―	―

ClouDr Group Limited Corporate Events

ClouDr Group Limited AGM Resolutions Passed with Strong Support

ClouDr Group Limited successfully conducted its Annual General Meeting on June 11, 2025, where all proposed resolutions were passed with overwhelming support. Key resolutions included the re-election of directors, re-appointment of auditors, and granting of mandates for share buy-back and issuance, reflecting strong shareholder confidence in the company’s governance and strategic direction.